Literature DB >> 7438694

Factors influencing nortriptyline steady-state kinetics: plasma and saliva levels.

P Kragh-Sørensen, N E Larsen.   

Abstract

Proportionality between dose and steady-state nortriptyline (NT) plasma levels was found both during initial treatment and after long-term treatment (years) within the NT Plasma level range of 20 to 296 ng/ml. There were day-to-day variations of 10% to 20% (coefficient of variation) but no systematic changes in plasma levels over time. A significant age variation in NT plasma levels was found in 116 patients. Patients over 70 yr of age (n = 23) had higher levels than other age groups (p < 0.001) dose corrected; p < 0.0001 dose and weight corrected). It was found that during episodes of acute inflammatory diseases NT steady-state plasma levels rose after a change in sedimentation rate. Our data show that the use of saliva rather than plasma in therapeutic drug level monitoring of NT cannot be recommended because the saliva/plasma ratio varied both intra- and interindividually by factors of from 2 to 4.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7438694     DOI: 10.1038/clpt.1980.237

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  16 in total

1.  Population pharmacokinetics and pharmacodynamics: potential use for gathering dose-concentration-response.

Authors:  M Jerling
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1996 Apr-Jun       Impact factor: 2.441

2.  Cardiovascular effects of amitriptyline in the treatment of elderly depressed patients.

Authors:  P Christensen; H Y Thomsen; O L Pedersen; P Thayssen; H Oxhøj; P Kragh-Sørensen; L F Gram
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

Review 3.  Pharmacokinetic optimisation of tricyclic antidepressant therapy.

Authors:  M Furlanut; P Benetello; E Spina
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

4.  Two prospective dosing methods for nortriptyline.

Authors:  P J Perry; J L Browne; B Alexander; M T Tsuang; A D Sherman; F J Dunner
Journal:  Clin Pharmacokinet       Date:  1984 Nov-Dec       Impact factor: 6.447

5.  Dose-dependent kinetics of imipramine in elderly patients.

Authors:  M Bjerre; L F Gram; P Kragh-Sørensen; C B Kristensen; O L Pedersen; M Møller; P Thayssen
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

6.  Plasma protein binding of imipramine in patients with rheumatoid arthritis.

Authors:  C B Kristensen
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

7.  Overdosage of antidepressants: clinical and pharmacokinetic aspects.

Authors:  O L Pedersen; L F Gram; C B Kristensen; M Møller; P Thayssen; M Bjerre; P Kragh-SøRensen; N A Klitgaard; E Sindrup; P Hole; M Brinklø
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

8.  The demethylation of amitriptyline: a cross-over study of steady-state plasma levels of amitriptyline and nortriptyline in depressed patients.

Authors:  J E Burch
Journal:  Psychopharmacology (Berl)       Date:  1983       Impact factor: 4.530

9.  Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6--an evaluation with the nonparametric maximum likelihood method.

Authors:  M Jerling; Y Merlé; F Mentré; A Mallet
Journal:  Br J Clin Pharmacol       Date:  1994-11       Impact factor: 4.335

10.  Amitriptyline dosage prediction in elderly patients from plasma concentration at 24 hours after a single 100mg dose.

Authors:  S Dawling; S Ford; D C Rangedara; R R Lewis
Journal:  Clin Pharmacokinet       Date:  1984 May-Jun       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.